OIPE JC154
SEP 0 3 2002
PATENT & TRADEMARK OFFICE



| Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** | Applicant Whitley et al. | |
| | Filing Date June 29, 2001 | Group |

**U.S. PATENT DOCUMENTS**

| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date if Appropriate |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | Yes | No |
| DL | | WO 94/14971 | 07/07/94 | PCT | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | **OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)** |
|---|---|
| AL | Supplementary European Search Report in EP 98 966 139.2 dated July 30, 2002 |
| | |

| Examiner | Date Considered 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE DEC 11 2001 PATENT & TRADEMARK OFFICE TC1600

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

**U.S. PATENT DOCUMENTS**

| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| | A1 | 5,231,012 | 7/27/93 | Mosmann *et al.* | 435 | 69.52 | |
| | A2 | 5,328,688 | 7/12/94 | Roizman, B. | 424 | 205.1 | |
| | A3 | 5,328,989 | 7/12/94 | Vellekamp *et al.* | 530 | 351 | |
| | A4 | 5,585,096 | 12/17/96 | Martuza *et al.* | 424 | 93.2 | |
| | A5 | 5,641,651 | 6/24/97 | Roizman, B. | 435 | 69.1 | |

**FOREIGN PATENT DOCUMENTS**

| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes | Translation No |
|---|---|---|---|---|---|---|---|---|
| | B1 | 0 302 429 B1 | 7/28/93 | EPO | | | | |
| | B2 | WO 00/40734 | 7/13/00 | PCT | | | | |

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|---|---|---|
| | C1 | Allione, *et al.*, "Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants," *Cancer Research* 54:6022-6026 (1994). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE DEC 11 2001 PATENT & TRADEMARK OFFICE TC 1800

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|---|---|
| | C2 | Andreansky, *et al.*, "The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors," *Proc. Natl. Acad. Sci. USA* **93**:11313-11318 (1996). |
| | C3 | Andreansky, *et al.*, "Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors," *Cancer Research* **57**:1502-1509 (1997). |
| | C4 | Andreansky, *et al.*, "Treatment of Intracranial Gliomas in Immunocompetent Mice Using Herpoes Simplex Viruses that Express Murine Interleukins," *Gene Therapy* **5**:121-130 (1998). |
| | C5 | Aoki, *et al.*, "Expression of Murine Interleukin-7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity *in vivo*," *Proc. Natl. Acad. Sci. USA* **89**:3850-3854 (1992). |
| | C6 | Asher, *et al.*, "Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor-α, Evidence for Paracrine Immune Effects of Tumor Necrosis Factor against Tumors," *J. Immunology* **146**:3227-3234 (1991). |
| | C7 | Ausman, *et al.*, "Studies on the Chemotherapy of Experimental Brain Tumors: Development of an Experimental Model," *Cancer Research* **30**:2394-2400 (1970). |
| | C8 | Beutler, *et al.*, "Control of Cachectin (Tumor Necrosis Factor) Syntheses: Mechanisms of Endotoxin Resistance," *Science* **232**:977-980 (1986). |
| | C9 | Blankenstein, *et al.*, "Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor α Gene Transfer," *J. Exp. Med.* **173**:1047-1052 (1991). |
| | C10 | Caruso, *et al.*, "Adenovirus-mediated Interleukin-12 Gene Therapy for Metastatic Colon Carcinoma." *Proc. Natl. Acad. USA* **93**:11302-11306 (1996). |
| | C11 | Chambers, *et al.*, "Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in a *Scid* Mouse Model of Human Malignant Glioma," *Proc. Natl. Acad. Sci. USA* **92**:1411-1415 (1995). |
| | C12 | Cheng, *et al.*, "*In vivo* Promoter Activity and Transgene Expression in Mammalian Somatic Tissues Evaluated by Using Particle Bombardment," *Proc. Natl. Acad. Sci. USA* **90**:4455-4459 (1993). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE DEC 1 1 2001 PATENT & TRADEMARK OFFICE

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|---|---|
| | C13 | Cho, *et al.*, "IL-6 Undergoes Transition from *in vitro* Autocrine Growth Factor to *in vivo* Growth Inhibitor of B Lymphoma Cells," *J. Biomed. Sci.* 4:201-207 (1997). |
| | C14 | Chou, *et al.*, "Mapping of Herpes Simplex Virus-1 Neurovirulence to $\gamma_1$34.5, a Gene Nonessential for Growth in Culture," *Science* **250**:1262-1266 (1990). |
| | C15 | Chou, *et al.*, "Differential Response of Human Cells to Deletions and Stop Codons in the $\gamma_1$34.5 Gene of Herpes Simplex Virus," *J. Virology* **68**:8304-8311 (1994). |
| | C16 | Couldwell, *et al.*, "Malignant Glioma Modulation of Immune Function: Relative Contribution of Different Soluble Factors," *J. Neuroimmunol.* **33**:89-96 (1991). |
| | C17 | Devos, *et al.*, "Molecular Cloning of Human Immune Interferon cDNA and Its Expression in Eukaryotic Cells," *Nucl. Acids Res.* **10**:2487-2501 (1982). |
| | C18 | Douvdevani, *et al.*, "Reduced Tumorigenicity of Fibrosarcomas which Constitutively Generate IL-1α Either Spontaneously or Following IL-1α Gene Transfer," *Int. J. Cancer* **51**:822-830 (1992). |
| | C19 | Dranoff, *et al.*, "Activities if Granulocyte-Macrophage Colony-Stimulating Factor Revealed by Gene Transfer and Gene Knockout Studies," *Stem Cells* **12**:173-184 (1994). |
| | C20 | Fakhrai, *et al.*, "Construction and Characterization of Retroviral Vectors for Interleukin-2 Gene Therapy," *J. Immunother.* **20**:437-448 (1997). |
| | C21 | Fearon, *et al.*, "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response," *Cell* **60**:397-403 (1990). |
| | C22 | Finke, *et al.*, "Increase of Proliferation Rate and Enhancement of Antitumor Cytoxicity of Expanded Human $CD3^+CD56^+$ Immunologic Effector Cells by Receptor-mediated Transfection with the Interleukin-7 Gene," *Gene Therapy* **5**:31-39 (1998). |
| | C23 | Golumbeck, *et al.*, "Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4," *Science* **254**:713-716 (1991). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE
DEC 1 1 2001
PATENT & TRADEMARK OFFICE

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|---|---|---|
| | C24 | Goodwin, *et al.*, "Human Interleukin7: Molecular Cloning and Growth Factor Activity on Human and Murine B-Lineage Cells," *Proc. Natl. Acad. Sci. USA* **86**:302-306 (1989). |
| | C25 | Gray, *et al.*, "Expression of Human Immune Interferon cDNA in *E. coli* and Monkey Cells," *Nature*, **295**:503-508 (1982). |
| | C26 | Hock, *et al.*, "Interleukin-7 Induces $CD4^+$ T Cell Dependent Tumor Rejection," *J. Exp. Med.* **174**:1291-1298 (1991). |
| | C27 | Jenkins, *et al.*, "Herpes Simplex Virus 1 Recombinants with Noninverting Genomes Frozen in Different Isomeric Arrangements are Capable of Independent Replication," *J. Viol.* **59**:494-499 (1986). |
| | C28 | Krüger-Krasagakes, *et al.*, "Production of Cytokines by Human Melanoma Cells and Melanocyted," *Cancer Research* **139**:155-168 (1995). |
| | C29 | Lagunoff, *et al.*, "The Regulation of Synthesis and Properties of the Protein Product of Open Reading Frame P of the Herpes Simplex Virus 1 Genome," *J. Virol.* **69**:3615-3623 (1995). |
| | C30 | Lee, *et al.*, "Isolation and Characterization of a Mouse Interleukin cDNA Clone that Expresses B-Cell Stimulatory Factor 1 Activities and T-cell and Mast-cell-Stimulating Activities," *Proc. Natl. Acad. Sci. USA* **83**:2061-2065 (1986). |
| | C31 | Lukacs, *et al.*, Transgene-induced Production of IL-4 Alters the Development and COllagen Expression of T Helper Cell 1-type Pulmonary Granulomas," *J. Immunol.* **158**:4478-4484 (1997). |
| | C32 | Maeda, *et al.*, "Cloning of Interleukin 2 mRNAs From Human Tonsils," *Biochem. Biophys. Res. Com.* **115**:1040-1047 (1983). |
| | C33 | Maliszewski, *et al.*, "Bovine GM-CSF: Molecular Cloning and Biological Activity of the Recombinant Protein," *Mol. Immunol.* **25**:843-850 (1988). |
| | C34 | March, *et al.*, "Cloning, Sequence and Expression of Two Distinct Human Interleukin-1 Complementary DNAs," *Nature* **315**:641-647 (1985). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC191 DEC 11 2001 PATENT & TRADEMARK OFFICE

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|---|---|
| | C35 | Markert, *et al.*, "Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Muitants that Retain Susceptibility to Acyclovir," *Neurosurg.* **32**:597-603 (1993). |
| | C36 | Martuza, *et al.*, "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant," *Science* **252**:854-856 (1991). |
| | C37 | Moore, *et al.*, "Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI," *Science* **248**:1230-1234 (1990). |
| | C38 | Moore, *et al.*, "Interleukin-10," *Annu. Rev. Immunol.* **11**:165-190 (1993). |
| | C39 | Moriuchi, *et al.*, "Enhanced Tumor Cell Killing in the Presence of Ganciclovir by Herpes Simplex Virus Type 1 Vector-directed Coexpression of Human Tumor Necrosis Factor-α and Herpes Simplex Virus Thymidine Kinase," *Cancer Research* **58**:5731-5737 (1998). |
| | C40 | Mulé, *et al.*, "Cellular Mechanisms of the Antitumor Activity of Recombinant IL-6 in Mice," *J. Immunol.* **148**:2622-2629 (1992). |
| | C41 | Porgador, *et al.*, "Immunotherapy Via Gene Therapy: Comparison of the Effects of Tumor Cells Transduced with the Interleukin-2, Interleukin-6, or Interferon-γ Genes," *J. Immunother.* **14**:191-201 (1993). |
| | C42 | Porgador, *et al.*, "Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastatic Cells," *Cancer Research* **52**:3679-3686 (1995). |
| | C43 | Post, *et al.*, "A Generalized Technique for Deletion of Specific Genes in Large Genomes: α Gene 22 of Herpes Simplex Virus 1 is Not Essential for Growth," *Cell* **25**:227-232 (1981). |
| | C44 | Ram, *et al.*, "*In vivo* Transfer of the Human Interleukin-2 Gene: Negative Tumoricidal Results in Experimental Brain Tumors," *J. Neurosurg.* **80**:535-540 (1994). |
| | C45 | Ram, *et al.*, "Therapy of Malignant Brain Tumors by Intratumoral Implantation of Retroviral Vector-producing Cells," *Nature Medicine* **3**:1354-1361 (1997). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC03 DEC 11 2001 PATENT & TRADEMARK OFFICE

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| | | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) |
|---|---|---|
| | C46 | Renauld, *et al.*, "Human P40/IL-9: Expression in Activated CD4$^+$T Cells, Genomic Organization, and Comparison with the Mouse Gene," *J. Immunol.* **144**:4235-4241 (1990). |
| | C47 | Restifo, *et al.*, "Identification of Human Cancers Deficient in Antigen Processing," *J. Exp. Med.* **177**:265-272 (1993). |
| | C48 | Richter, *et al.*, "Interleukin 10 Transfected into Chinese Hamster Ovary Cells Prevents Tumor Growth and Macrophage Infiltration," *Cancer Research* **53**:4131-4137 (1993). |
| | C49 | Rinderknecht, *et al.*, "Natural Human Interferon-γ. Complete Amino Acid Sequence Determination of Sites of Glycosylation," *Biol. Chem.* **259**:6790-6797 (1984). |
| | C50 | Roizman, *et al.*, "Genetic Engineering of Novel Genomes of Large DNA Viruses," *Science* **229**:1208-1218 (1985). |
| | C51 | Roszman, *et al.*, "Modulation of T-Cell Function by Gliomas," *Immunology Today* **12**:370-374 (1991). |
| | C52 | Schumacher, *et al.*, "Use of Clinically Relevant Human-*scid*-mouse Models in Metastasis Research," *TIBTECH* **15**:239-241(1997). |
| | C53 | Shih, *et al.*, "Expression of Hepatitis B Virus *S* Gene by Herpes Simplex Virus Type 1 Vectors Carrying α- and β-Regulated Gene Chimeras," *Proc. Natl. Acad. Sci. USA* **81**:5867-5870 (1984). |
| | C54 | Souza, *et al.*, "Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells," *Science* **232**:60-65 (1986). |
| | C55 | Tada, *et al.*, "Cellular and Cytokine Responses of the Human Central Nervous System to Intracranial Administration of Tumor Necrosis Factor α for the Treatment of Malignant Gliomas," *Cancer Immunol. Immunother.* **36**:251-259 (1993). |
| | C56 | Taniguchi, *et al.*, "Structure and Expression of a Cloned cDNA for Human Interleukin-2," *Nature* **302**:305-310 (1983). |

| EXAMINER | DATE CONSIDERED 6/14/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC100 DEC 11 2001 PATENT & TRADEMARK OFFICE

| Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Atty. Docket No. 27373/33716 | Serial No. 09/869,674 |
|---|---|---|---|
| **INFORMATION DISCLOSURE STATEMENT** *(Use several sheets if necessary)* | | Applicant Whitley et al | |
| | | Filing Date 6/29/01 | Group To be assigned |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|---|---|---|
| | C57 | Takamiya, *et al.*, "Gene Therapy of Malignant Brain Tumors: A Rat GLioma Line Bearing the Herpes Simplex Virus Type 1-Thymidine Kinase Gene and Wild Type Retrovirus Kills other Tumor Cells," *J. Neurosci. Res.* **33**:493-503 (1992). |
| | C58 | Tepper, *et al.*, "Review: Experimental and Clinical Studies of Cytokine Gene-Modified Tumor Cells," *Human Gene Therapy* **5**:153-164 (1994). |
| | C59 | Tjuvajev, *et al.*, "RG-2 Glioma Growth Attenuation and Severe Brain Edems Caused by Local Production of Interleukin-2 and Interferon-γ," *Cancer Research* **55**:1902-1910 (1995). |
| | C60 | VanCott, *et al.*, "Regulation of Mucosal and Systemic Antibody Responses by T Helper Cell Subsets, Macrophages, and Derived Cytokines Following Oral Immunization with Live Recombinant *Salmonella*," *J. Immunology* **156**:1504-1514 (1996). |
| | C61 | Vieira, *et al.*, "Isolation and Expression of Human Cytokine Synthesis Inhibitory Factor cDNA Clones: Homology to Epstein-Barr Virus Open Reading Frame BCRFI," *Proc. Natl. Acad. Sci. USA* **88**:1172-1176 (1991). |
| | C62 | Vigon, *et al.*, "Molecular Cloning and Characterization of *MPL*, the Human Homolog of the V-*mpl* Oncogene: Identification of a Member of the Hematopoietic Growth Factor Receptor Superfamily," *Proc. Natl. Acad. Sci. USA* **89**:5640-5644 (1992). |
| | C63 | Wei, *et al.*, "Enhancement of Interleukin-4-Mediated Tumor Regression in Athymic Mice by *In Situ* Retroviral Gene Transfer," *Human Gene Therapy* **6**:437-443 (1995). |
| | C64 | Wiranowska, *et al.*, "Evaluation of Blood-brain Barrier Permeability and the Effect of Interferon in Mouse Glioma Model," *J. Neuro-Oncology* **14**:225-236 (1992). |
| | C65 | Yu, *et al.*, " Treatment of Glioma by Engineered Interleukin 4-Secreting Cells," *Cancer Research* **53**:3125-3128 (1993). |

| EXAMINER | DATE CONSIDERED 6/10/04 |
|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.